Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

SERRETTA, Vincenzo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.752
EU - Europa 11.840
AS - Asia 8.989
SA - Sud America 1.338
AF - Africa 250
OC - Oceania 31
Continente sconosciuto - Info sul continente non disponibili 12
Totale 41.212
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.386
RU - Federazione Russa 3.366
SG - Singapore 3.179
CN - Cina 2.276
IT - Italia 2.166
FI - Finlandia 1.150
BR - Brasile 1.067
DE - Germania 1.048
UA - Ucraina 1.012
HK - Hong Kong 899
VN - Vietnam 825
IE - Irlanda 596
PL - Polonia 581
GB - Regno Unito 535
FR - Francia 461
BD - Bangladesh 389
SE - Svezia 380
JP - Giappone 360
KR - Corea 220
IN - India 216
CA - Canada 180
BE - Belgio 103
RO - Romania 97
AR - Argentina 94
IQ - Iraq 94
MX - Messico 80
NL - Olanda 79
CI - Costa d'Avorio 69
TR - Turchia 65
AT - Austria 59
ZA - Sudafrica 53
PK - Pakistan 52
ES - Italia 47
VE - Venezuela 47
UZ - Uzbekistan 43
ID - Indonesia 42
CH - Svizzera 37
MY - Malesia 35
CO - Colombia 34
AE - Emirati Arabi Uniti 31
CZ - Repubblica Ceca 31
EC - Ecuador 30
PH - Filippine 30
CL - Cile 29
SA - Arabia Saudita 27
AU - Australia 26
EG - Egitto 25
MA - Marocco 25
JM - Giamaica 22
JO - Giordania 21
IL - Israele 18
IR - Iran 18
AZ - Azerbaigian 17
CR - Costa Rica 16
KZ - Kazakistan 16
TN - Tunisia 16
DZ - Algeria 14
LB - Libano 14
GR - Grecia 13
KE - Kenya 13
NP - Nepal 13
PY - Paraguay 13
AL - Albania 12
BH - Bahrain 12
HN - Honduras 12
LT - Lituania 12
GE - Georgia 11
GT - Guatemala 10
RS - Serbia 10
OM - Oman 9
TH - Thailandia 9
TW - Taiwan 9
UY - Uruguay 9
BG - Bulgaria 8
AO - Angola 7
BB - Barbados 7
DO - Repubblica Dominicana 7
NG - Nigeria 7
PA - Panama 7
PE - Perù 7
BO - Bolivia 6
EU - Europa 6
KW - Kuwait 6
MD - Moldavia 6
NI - Nicaragua 6
PS - Palestinian Territory 6
PT - Portogallo 6
AM - Armenia 5
NZ - Nuova Zelanda 5
BA - Bosnia-Erzegovina 4
DK - Danimarca 4
ET - Etiopia 4
PR - Porto Rico 4
SV - El Salvador 4
SY - Repubblica araba siriana 4
TT - Trinidad e Tobago 4
XK - ???statistics.table.value.countryCode.XK??? 4
BN - Brunei Darussalam 3
BY - Bielorussia 3
CM - Camerun 3
Totale 41.158
Salva come PNG Salva come JPEG
Città #
Ashburn 2.480
Singapore 2.053
Fairfield 1.631
San Jose 1.272
Chandler 1.084
Woodbridge 868
Hong Kong 847
Wilmington 824
Ann Arbor 759
Houston 708
Seattle 640
Dublin 594
Jacksonville 534
Cambridge 515
Zgierz 511
Moscow 427
Medford 415
Beijing 398
Tokyo 340
New York 307
Los Angeles 293
Santa Clara 288
Des Moines 284
Nanjing 275
Ho Chi Minh City 268
Frankfurt am Main 266
Princeton 266
Dallas 224
Lauterbourg 221
Boardman 215
Hanoi 203
Palermo 190
Helsinki 182
Council Bluffs 181
Altamura 171
The Dalles 161
Hefei 157
Tulsa 149
Lawrence 137
Milan 132
Buffalo 129
Dearborn 122
Nanchang 109
San Diego 107
São Paulo 99
Brussels 98
Shenyang 92
Chicago 87
Orem 79
Hebei 73
Rome 73
Changsha 70
Abidjan 69
Tianjin 65
Jiaxing 62
Columbus 61
Ludwigshafen am Rhein 61
Nuremberg 61
Montreal 59
London 57
Denver 54
Munich 52
Brooklyn 50
Da Nang 50
Guangzhou 47
Seongnam 46
Toronto 46
Jinan 45
Kumar 43
Saint Petersburg 43
Amsterdam 42
Warsaw 42
Chennai 40
Verona 40
Zhengzhou 38
Redwood City 37
Haiphong 36
Phoenix 36
Venice 36
Baghdad 34
Bremen 34
Tashkent 34
Nave 33
Atlanta 32
Auburn Hills 30
Rio de Janeiro 30
San Francisco 30
Seoul 30
Belo Horizonte 29
Boston 29
City of London 29
Johannesburg 29
Falls Church 26
Ningbo 26
San Mateo 26
Manchester 25
San Paolo di Civitate 25
Washington 25
Paris 24
Vienna 24
Totale 24.530
Salva come PNG Salva come JPEG
Nome #
S9-Fibronectin, EGF-R, HB-EGF:biomarkers of urothelial damage during intravesical adjuvant therapy? 613
PROSPECTIVE, RANDOMIZED, CROSSOVER COMPARISON OF SUBLINGUAL APOMORPHINE (3 mg) WITH ORAL SILDENAFIL (50 mg) FOR MALE ERECTILE DYSFUNCTION 500
Clinical and biochemical markers of visceral adipose tissue activity: Body mass index, visceral adiposity index, leptin, adiponectin, and matrix metalloproteinase-3. Correlation with Gleason patterns 4 and 5 at prostate biopsy 348
Characterization of human infiltrating and circulating gamma-delta t cells in prostate cancer 308
Drinking water source and cigarette smoking in transitional cell carcinoma of the bladder. 290
Manuale di Urologia e Andrologia. Capitolo 1: Anatomia dell'apparato genito-urinario 288
Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel: A Prospective Single-Center Study 284
A phase I-II study on intravesical Gemcitabine in superficial bladder papillary tumors 283
A 1-year maintenance after early adjuvant intravesical chemotherapy has a limited efficacy in preventing recurrence of intermediate risk non-muscle-invasive bladder cancer. 281
Correlation between chronic prostatitis syndrome and pelvic venous disease. A survey of 2554 urologic outpatients 279
Prospective, randomized, crossover comparison of sublingual apomorphine (3 mg) with oral sildenafil (50 mg) for male erectile dysfunction. 275
Whatsapp messenger as a tool for the multidisciplinary management in everyday clinical practice 268
Correlation between GP-170 expression, prognosis, and chemoresistance of superficial bladder carcinoma 263
Cytokine gene expression in the tunica albuginea 
of patients with Peyronie’s disease. Pilot study with 
a control group 247
Can we clinically distinguish anejaculation from retrograde ejaculation in patients on α1A-blockers therapy for lower urinary tract symptoms? 243
Segmental resection of distal ureter with termino-terminal ureteric anastomosis vs bladder cuff removal and ureteric re-implantation for upper tract urothelial carcinoma: results of a multicentre study 238
Modificazioni del PSA dopo terapia antibiotica in pazienti candidati alla biopsia prostatica. 237
Cytokines gene expression in the tunica albuginea of patients with Peyronie’s disease. Pilot study with a control group 232
Clinical implications of a rare renal entity: Pleomorphic Hyalinizing Angiectatic Tumor (PHAT) 223
Il carcinoma prostatico in Calabria e Sicilia. 222
Hypofractionated postoperative helical tomotherapy in prostate cancer: a mono-institutional report of toxicity and clinical outcomes 222
Intravesical chemotherapy for intermediate risk non-muscle invasive bladder cancer recurring after a first cycle of intravesical adjuvant therapy 220
WHATSAPP MESSENGER AS A REAL-TIME TOOL FOR A LONG-DISTANCE ACTIVITY OF A MULTIDISCIPLINARY 219
Preliminary report of a multicentric study on environmental risk factors in Ta-T1 transitional cell carcinoma of the bladder 217
A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia. 217
Analisi preliminare dei fattori demografici ed eziopatogenetici in pazienti affetti da carcinoma vescicale a medio rischio di recidiva 212
Does the Compliance to Intravesical BCG Differ between Common Clinical Practice and International Multicentric Trials? 212
Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder 212
Cytokines gene expression in the tunica albuginea in patients with Peyronie’s disease. Pilot study with a control group 211
Recurrence and progression according to stage at re-TUR in t1g3 bladder cancer patients treated with BCG: Not as bad as previously thought 211
POSITIVITA’ DELL’NMP22 E NEGATIVITA’ CISTOSCOPICA E CITOLOGICA. QUALE SIGNIFICATO ATTRIBUIRE? 209
Mitomycin C from birth to adulthood 208
Valore clinico della riduzione del PSA in soggetti candidati all’agobiopsia prostatica 207
Management of bicalutamide induced gynaecomastia. A randomized study comparing therapy versus prophylaxis with tamoxifen. 207
Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of the bladder: Phase I-II study on marker lesions 206
The activity of intravesical hyaluronic acid and chondroitin sulfate administration on urothelial gene expression. Preliminary results on the epidermal growth factor receptor and fibronectin gene expression evaluated in bladder washings of patients affected by non muscle-invasive bladder cancer 205
La terapia dei tumori vescicali superficiali: lo stato attuale 203
TERAPIA CONSERVATIVA DELL'UROTELIOMA VESCICALE T1G3. RISULTATI SU 235 PAZIENTI 203
Sarcomatoid carcinoma of urinary bladder: Immunohistochemical study of an uncommon case 203
How Can the COVID-19 Pandemic Lead to Positive Changes in Urology Residency? 203
Fumo, risorsa idrica ed altri fattori di rischio nel carcinoma vescicale superficiale 201
Distribution of smoking, water resource and other environmental factors in patients affected by superficial bladder cancer 200
Carcinoma uroteliale in cisti pielogena 200
Genitourinary Symptoms-Patient Help-Seeking and General Practitioner Management: An Outpatient Based Survey at a Tertiary Hospital in Southern Italy 200
Intravesical gemcitabine in superficial bladder tumours preliminary results of a phase I-II study 198
Correlation between BMI and the pathological features of prostate cancer at biopsy 195
La p53 nel tumore vescicale superficiale (Ta-T1, G1-3) 194
INTRAVESICAL GEMCITABINE IN SUPERFICIAL BLADDER TUMOURS.RESULTS OF A PHASE I-II STUDY 193
Chemioterapia adiuvante e fattori di rischio ambientale nel carcinoma vescicale superficiale a medio rischio di recidiva. Uno studio prospettico randomizzato del Gruppo Studio Tumori Urologici (GSTU). 193
Re: Urinary pH is Highly Associated With Tumor Recurrence During Intravesical Mitomycin C Therapy for Nonmuscle Invasive Bladder Tumor 193
PSA reduction (after antibiotics) permits to avoid or postpone prostate biopsy in selected patients 192
Multiplicity and history have a detrimental effect on survival in patients with T1G3 bladder tumors selected for conservative treatment. 192
T1HG Bladder Tumours: So Many Papers, Do We Need Them? Yes, We Do! 190
Ruolo prognostico della p53 nel tumore vescicale superficiale. Correlazione con recidiva e progressione – 189
Fumo di sigaretta e risorsa idrica in pazienti affetti da carcinoma vescicale superficiale. XV Congresso Nazionale SIUro, Giardini Naxos 3-6 novembre 2005. 1. 188
Chemioterapia adiuvante e fattori di rischio ambientale nel carcinoma vescicale superficiale a medio rischio di recidiva. Uno studio prospettico randomizzato del Gruppo Studi Tumori Urologici (GSTU) 188
BIOMARKERS OF UROTHELIAL DAMAGE IN PATIENTS TREATED BY ADJUVANT INTRAVESICAL THERAPY 188
Does Exist A Correlation Between BMI and Gleason Patterns 4 and 5 At Prostate Biopsy? 188
Fibronectin (FN), epidermal growth factor-receptor (EGF-R) and heparin-binding epidermal growth factor-like (HB-EGF) urinary expressions and topical toxicity of adjuvant intravesical therapy for non muscle invasive bladder cancer (NMI-BC) 187
PROSTATA (PROSTATITI, IPERTROFIA PROSTATICA, CANCRO DELLA PROSTATA) 186
Plasma levels of angiogenetic markers in men candidate to prostate biopsy 186
IS VISCERAL ADIPOSITY INDEX (VAI)RELATED TO PROSTATE CANCER DETECTED BY BIOPSY? 186
Epidermal Growth Factor Receptor (EGFR) Cell Expression During Adjuvant Treatment After Transurethral Resection for Non-Muscle-Invasive Bladder Cancer: A New Potential Tool to Identify Patients at Higher Risk of Disease Progression 186
Modificazioni del PSA dopo terapia antibiotica in pazienti candidati alla biopsia prostatica 185
Attività lavorativa e fattori di rischio ambientale in pazienti affetti da carcinoma vescicale superficiale. 185
Studio pilota sul valore predittivo dei livelli plasmatici di 9 fattori angiogenetici nella selezione di pazienti candidati alla biopsia prostatica 184
Segmental ureterectomy vs. radical nephroureterectomy for ureteral carcinoma in patients with a preoperative glomerular filtration rate less than 90 ml/min/1.73 m2: A multicenter study 184
Fattori di rischio ambientali nella storia naturale del carcinoma vescicale superficiale. 183
The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer 183
The clinical value of PSA increase during intravesical adjuvant therapy for nonmuscle-invasive bladder cancer. 183
High-Grade T1 on Re-Transurethral Resection after Initial High-Grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional Study 182
CHEMIOPROFILASSI PRECOCE CON EPIRUBICINA AD ALTA DOSE NEL CARCINOMA VESCICALE SUPERFICIALE. STUDIO RANDOMIZZATO DEL GSTU 181
An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer 181
TUR AND ADJUVANT INTRAVESCICAL CHEMOTHERAPY IN T1G3 BLADDER TUMORS. RECURRENCE, PROGRESSION AND SURVIVAL IN 137 SELECTED PATIENTS FOLLOWED UP TO 20 YEARS. 180
Studio randomizzato sul ruolo del mantenimento nella chemioprofilassi endovescicale precoce dopo TUR con Epirubicina. XVI Congresso Nazionale Società Italiana di Urologia Oncologica. 30 Novembre - 3 Dicembre 2006. Arch. Ital. Urol. Androl. vol. , pp. 71. ISBN/ISSN: 1124-3562. 179
Fattori di rischio ambientale nel carcinoma vescicale superficiale. Risultati su 577 pazienti sottoposti a chemioterapia endovescicale adiuvante 179
Are referral centers for non-muscle-invasive bladder cancer compliant to EAU guidelines? A report from the vesical antiblastic therapy Italian study 178
Compliance to therapy with Dapoxetine in comparison to a conventional selective serotonin reuptake inhibitor (Citalopram) in 118 patients with premature ejaculation. 178
Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer 177
Cigarette Smoking Status at Diagnosis and Recurrence in Intermediate-risk Nonemuscle-invasive Bladder Carcinoma 177
Survival risk factors in T1G3 non-muscle-invasive (NMI) bladder cancer consevatively treated. Long term results. 176
Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non-muscle-invasive Bladder Cancer 176
Although rare, severe complications following intravesical bacillus Calmette-Guerin treatment should not be overlooked! 175
Intravesical gemcitabine is superficial bladder tumours. Results of a phase I-II study 174
Water Chlorination and other environmental factors in bladder cancer. Result of a multicentre study. 174
Acute and late toxicity and preliminary outcomes report of moderately hypofractionated helical tomotherapy for localized prostate cancer: a mono-institutional analysis 174
Efficacia del mantenimento nella chemioprofilassi endovescicale precode dopo TUR. Risultati di uno studio randomizzato multicentrico. 173
ESTRAMUSTINA FOSFATO VS ASSOCIAZIONE A BASSA DOSE DI ESTRAMUSTINA FOSFATO E ETOPOSIDE NEL CARCINOMA PROSTATICO ORMONOREFRATTARIO (HRPC). STUDIO RANDOMIZZATO DI FASE II DEL GRUPPO STUDI TUMORI UROLOGICI (GSTU) 173
A RANDOMIZED STUDY EVALUATING MAINTENANCE SCHEDULE IN EARLY ADJUVANT CHEMOTHERAPY FOR INTERMEDIATE RISK NON-MUSCLE-INVASIVE BLADDER CANCER. 173
A case of renal carcinoma metastasis simulating a thyroid goiter 173
Cigarette smoking and drinking water source: Correlation with clinical features and pathology of superficial bladder carcinoma. 172
PSA and second-line therapy of hormone refractory prostate carcinoma 172
Significato clinico della positività della NMP22 in pazienti in follow-up per carcinoma vescicale superficiale. Risultati a lungo termine 171
Impact of stage migration on bladder cancer: A slow but steady improvement in the long term survival rates after radical cystectomy in the last 25 years 171
Fattori di rischio ambientale nel carcinoma vescicale superficiale. Risultati su 577 pazienti sottoposti a chemioterapia endovescicale adiuvante. 170
Chemioterapia domiciliare nel carcinoma prostatico ormonorefrattario (HRPC). Studio di fase II del gruppo studio tumori urologici (GSTU). 170
A randomized phase II study of estramustine phosphate versus estramustine phosphate plus etoposide in hormone refractory prostate cancer (HRPC). 170
PLEOMORPHIC HYALINIZING ANGIOECTATIC TUMOR (PHAT) OF RENAL PARENCHYMA. FIRST CASE REPORTED IN LITERATURE 170
Ipertermia e chemioterapia nel tumore vescicale superficiale a medio-alto rischio:esperienza preliminare sulla tollerabilità. 169
STUDIO RANDOMIZZATO SUL RUOLO DEL MANTENIMENTO NELLA CHEMIOPROFILASSI ENDOVESCICALE PRECOCE DOPO TUR CON EPIRUBICINA 168
Totale 21.065
Salva come PNG Salva come JPEG
Categoria #
all - tutte 136.630
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 136.630
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.688 126 575 61 140 150 115 73 142 332 331 108 535
2022/20233.769 418 549 89 334 406 498 226 238 800 21 137 53
2023/20241.735 71 237 170 180 151 357 153 124 11 21 75 185
2024/20254.105 138 212 194 370 202 153 258 294 359 430 616 879
2025/202615.804 1.105 464 788 1.017 1.319 2.389 2.290 1.629 1.136 2.150 815 702
2026/2027825 825 0 0 0 0 0 0 0 0 0 0 0
Totale 42.047